Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.51 |
| ▸ | CNR2 | P34972 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | MARS1 | P56192 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267515 | 0.87 | CNR1 (0.49) | CNR1CNR2KMT2AHSD11B1CRHR1 | |
| SCHEMBL3268899 | 0.86 | CNR1 (0.48) | CNR1CNR2KMT2AHSD11B1CRHR1 | |
| SCHEMBL3267318 | 0.78 | CNR1 (0.45) | CNR1CNR2KMT2A | |
| SCHEMBL3367684 | 0.77 | CNR1 (0.65) | CNR1CNR2KMT2AMARS1 | |
| SCHEMBL3366114 | 0.77 | CNR1 (0.65) | CNR1CNR2KMT2AMARS1 | |
| SCHEMBL3629336 | 0.73 | CNR1 (0.66) | CNR1CNR2KMT2AMARS1 | |
| SCHEMBL3362851 | 0.70 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL5094249 | 0.70 | CNR1 (0.62) | CNR1CNR2 | |
| SCHEMBL3367640 | 0.70 | CNR1 (0.69) | CNR1CNR2 | |
| SCHEMBL3367034 | 0.69 | CNR1 (0.63) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781471-B2 | Diaryl triazolmethylamine derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| EP-1966167-B1 | DIARYLTRIAZOLMETHYLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-06-16 | — | — | EP | disclosed |
| US-20080293794-A1 | DIARYLTRIAZOLMETHYLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293794-A1 | DIARYLTRIAZOLMETHYLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | LTB4R2, LTB4R, CYSLTR1 | CNR1 31/4885CNR2 15/4885KMT2A 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.